Axonics, Inc. – NASDAQ:AXNX

Financial Health
0
1
2
3
4
5
6
7
8
9

Axonics stock price monthly change

+1.19%
month

Axonics stock price quarterly change

+0.09%
quarter

Axonics stock price yearly change

+30.31%
year

Axonics key metrics

Market Cap
3.62B
Enterprise value
2.47B
P/E
-44.77
EV/Sales
9.05
EV/EBITDA
-51.45
Price/Sales
9.77
Price/Book
4.69
PEG ratio
-1.43
EPS
-0.32
Revenue
316.94M
EBITDA
28.18M
Income
-15.95M
Revenue Q/Q
29.38%
Revenue Y/Y
7.10%
Profit margin
-21.81%
Oper. margin
-15.49%
Gross margin
72.22%
EBIT margin
-15.49%
EBITDA margin
8.89%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Axonics stock price history

Axonics stock forecast

Axonics financial statements

Axonics, Inc. (NASDAQ:AXNX): Profit margin
Jun 2023 22.70M -7.34M -32.34%
Sep 2023 93.1M 3.92M 4.22%
Dec 2023 109.73M 6.57M 5.99%
Mar 2024 91.40M -19.11M -20.91%
Axonics, Inc. (NASDAQ:AXNX): Analyst Estimates
Sep 2025 137.64M 12.05M 8.76%
Oct 2025 136.91M 9.82M 7.17%
Dec 2025 156.76M 14.04M 8.96%
Mar 2026 126.46M -2.01M -1.59%
  • Analysts Price target

  • Financials & Ratios estimates

Axonics, Inc. (NASDAQ:AXNX): Debt to assets
Jun 2023 648985000 33.28M 5.13%
Sep 2023 660747000 50.12M 7.59%
Dec 2023 719923000 82.35M 11.44%
Mar 2024 715561000 88.46M 12.36%
Axonics, Inc. (NASDAQ:AXNX): Cash Flow
Jun 2023 -19.20M -68.62M -6.76M
Sep 2023 12.34M -11.05M 878K
Dec 2023 5.63M -37.92M 578K
Mar 2024 -9.23M 138.23M 248K

Axonics alternative data

Axonics, Inc. (NASDAQ:AXNX): Employee count
Aug 2023 610
Sep 2023 610
Oct 2023 610
Nov 2023 610
Dec 2023 610
Jan 2024 610
Feb 2024 610
Mar 2024 797
Apr 2024 797
May 2024 797
Jun 2024 797
Jul 2024 797

Axonics other data

97.78% -2.22%
of AXNX is owned by hedge funds
44.30M -2.26M
shares is hold by hedge funds

Axonics, Inc. (NASDAQ:AXNX): Insider trades (number of shares)
Period Buy Sel
Feb 2023 0 23321
Mar 2023 0 15000
Apr 2023 0 22001
May 2023 0 7999
Jul 2023 0 1500
Aug 2023 0 14769
Sep 2023 0 7675
Dec 2023 0 8000
Jan 2024 0 98451
Transaction Date Insider Security Shares Price per share Total value Source
Option
SAMA RINDA officer: Chief Op.. Common Stock 28,000 N/A N/A
Option
KEESE KARI LEIGH officer: Chief Financial Officer
Common Stock 6,167 N/A N/A
Option
SAMA RINDA officer: Chief Op.. Performance-Based Restricted Stock Units 17,500 N/A N/A
Option
NOBLETT KAREN officer: Chief Me.. Common Stock 27,500 N/A N/A
Sale
NOBLETT KAREN officer: Chief Me.. Common Stock 11,288 $67.74 $764,604
Option
NOBLETT KAREN officer: Chief Me.. Performance-Based Restricted Stock Units 15,000 N/A N/A
Option
WOOCK JOHN officer: EVP, Chief Mktg/Strtgy..
Common Stock 28,000 N/A N/A
Sale
WOOCK JOHN officer: EVP, Chief Mktg/Strtgy..
Common Stock 15,899 $67.74 $1,076,935
Option
WOOCK JOHN officer: EVP, Chief Mktg/Strtgy..
Performance-Based Restricted Stock Units 17,500 N/A N/A
Option
FORD ALFRED J JR officer: Chief Co.. Common Stock 25,500 N/A N/A
Tuesday, 19 November 2024
zacks.com
Friday, 15 November 2024
prnewswire.com
Thursday, 7 November 2024
zacks.com
Friday, 27 September 2024
zacks.com
Thursday, 26 September 2024
businesswire.com
Wednesday, 25 September 2024
zacks.com
Wednesday, 18 September 2024
businesswire.com
Thursday, 1 August 2024
zacks.com
Monday, 20 May 2024
https://www.defenseworld.net
Thursday, 16 May 2024
businesswire.com
Tuesday, 30 April 2024
businesswire.com
Wednesday, 24 April 2024
prnewswire.com
Thursday, 4 April 2024
reuters.com
Friday, 29 March 2024
Zacks Investment Research
Friday, 15 March 2024
Zacks Investment Research
Wednesday, 28 February 2024
Zacks Investment Research
Wednesday, 31 January 2024
Zacks Investment Research
Monday, 8 January 2024
The Motley Fool
InvestorPlace
Schaeffers Research
Barrons
Reuters
Wednesday, 27 December 2023
Business Wire
Friday, 15 December 2023
Zacks Investment Research
Tuesday, 5 December 2023
Market Watch
Wednesday, 29 November 2023
Zacks Investment Research
Wednesday, 1 November 2023
Business Wire
Monday, 30 October 2023
Seeking Alpha
Zacks Investment Research
Friday, 27 October 2023
Zacks Investment Research
  • When is Axonics's next earnings date?

    Unfortunately, Axonics's (AXNX) next earnings date is currently unknown.

  • Does Axonics pay dividends?

    No, Axonics does not pay dividends.

  • How much money does Axonics make?

    Axonics has a market capitalization of 3.62B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 33.86% to 366.38M US dollars.

  • What is Axonics's stock symbol?

    Axonics, Inc. is traded on the NASDAQ under the ticker symbol "AXNX".

  • What is Axonics's primary industry?

    Company operates in the Healthcare sector and Medical - Devices industry.

  • How do i buy shares of Axonics?

    Shares of Axonics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Axonics's key executives?

    Axonics's management team includes the following people:

    • Mr. Raymond W. Cohen Chief Executive Officer & Director(age: 66, pay: $1,030,000)
    • Mr. Danny L. Dearen Pres & Chief Financial Officer(age: 62, pay: $738,900)
    • Dr. Karen L. Noblett M.D., M.A.S. Chief Medical Officer(age: 62, pay: $651,400)
    • Mr. Rinda K. Sama Chief Operating Officer(age: 46, pay: $644,730)
    • Mr. Alfred J. Ford Jr. Chief Commercial Officer(age: 54, pay: $569,360)
  • How many employees does Axonics have?

    As Jul 2024, Axonics employs 797 workers.

  • When Axonics went public?

    Axonics, Inc. is publicly traded company for more then 6 years since IPO on 31 Oct 2018.

  • What is Axonics's official website?

    The official website for Axonics is axonics.com.

  • Where are Axonics's headquarters?

    Axonics is headquartered at 26 Technology Drive, Irvine, CA.

  • How can i contact Axonics?

    Axonics's mailing address is 26 Technology Drive, Irvine, CA and company can be reached via phone at +94 93966322.

Axonics company profile:

Axonics, Inc.

axonics.com
Exchange:

NASDAQ

Full time employees:

797

Industry:

Medical - Devices

Sector:

Healthcare

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

26 Technology Drive
Irvine, CA 92618

CIK: 0001603756
ISIN: US05465P1012
CUSIP: 05465P101